A tumor-targeting RGD peptide-decorated nanoplatform uses near-infrared light to degrade cancer-driving BRD4 protein while enhancing anti-tumor immune responses in mice.
Synergistic immunotherapy enhancementThe RGD-targeted nanoplatform not only degraded BRD4 but also triggered immunogenic cell death and downregulated PD-L1, significantly boosting anti-PD-L1 checkpoint therapy in a bilateral tumor model.
What the researchers found
The PCN-CuS-JQ/RGD nanoplatform executes a multi-step delivery cascade: RGD peptide targets integrin-overexpressing tumor cells → the MOF carrier decomposes intracellularly, releasing CuS-JQ/RGD units → these enter the nucleus and bind BRD4 → NIR-II laser irradiation triggers photothermal BRD4 degradation. This process simultaneously induces immunogenic cell death (ICD) and downregulates PD-L1, creating synergy with anti-PD-L1 checkpoint blockade therapy. In bilateral tumor mouse models, the combination significantly enhanced immunotherapy efficacy beyond either approach alone.
Why it matters
Targeted protein degradation is one of the most exciting frontiers in cancer therapy, but current approaches (PROTACs) lack precise control and cause toxicity. By using light activation with peptide-guided targeting, this platform achieves spatiotemporal control — degrading cancer proteins only where and when the light is applied. The bonus of enhancing immunotherapy makes this a potentially transformative multi-modal approach to cancer treatment.
How the study worked
Preclinical mouse cancer model study. The nanoplatform was constructed using an Fe-porphyrin metal-organic framework (PCN(Fe)) as the carrier, decorated with CuS photothermal agents, BRD4 inhibitor JQ1, and RGD tumor-targeting peptide. MRI imaging confirmed tumor targeting. A 1064 nm NIR-II laser was used for photothermal activation. Anti-tumor efficacy was assessed in bilateral tumor-bearing mice with and without anti-PD-L1 combination therapy.
What this study cannot tell us
This is a preclinical mouse study, and translation to human cancer treatment faces significant challenges including light penetration depth for deep tumors, scalability of nanoplatform manufacturing, and potential toxicity of the multi-component system. The 1064 nm laser can penetrate tissue but has limits for deep-seated tumors. Long-term safety of the degradation products and the MOF carrier has not been assessed. The bilateral tumor model, while powerful, is a simplified representation of human cancer metastasis.
How to read the evidence
This is a preclinical proof-of-concept study in mouse cancer models. While the multi-modal approach and synergistic results are impressive, this is early-stage research that is far from clinical application.
When this study was published
Published in 2026 in Advanced Science, this represents cutting-edge nanotechnology research combining the latest advances in targeted protein degradation, photothermal therapy, and cancer immunology.
The bigger picture
This study sits at the intersection of several rapidly advancing fields: peptide-guided drug delivery, targeted protein degradation, photothermal therapy, and cancer immunotherapy. The use of RGD peptide for tumor targeting is a well-established approach that continues to find new applications. By combining peptide targeting with light-activated protein destruction and immune system activation, the platform represents a new paradigm for precision cancer therapy.
Questions still open
- How deep can the NIR-II laser effectively activate the nanoplatform in real tumor tissue?
- Could this approach be combined with endoscopic or fiber-optic light delivery for internal tumors?
- What are the long-term biodistribution and safety profiles of the PCN(Fe) carrier and its degradation products?
Common questions
What role does the RGD peptide play in this cancer treatment?
How does destroying one protein (BRD4) also boost the immune system against cancer?
Read the original research
A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23928
Citation
Wang, Luyi; Wu, Jiasha; Ji, Rui; Qiang, Sufeng; Shen, Yulin; Zuo, Yan; Jian, Shiqin; Liu, Siyao; Xu, Fusheng; Hu, Honggang; Hu, Xiaochun. (2026). A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23928. https://doi.org/10.1002/advs.202523928